Abstract 848P
Background
This observational real-world study used propensity score matching (PSM) to compare tumor lysis syndrome (TLS) associated mortality in patients (pts) with hematological malignancies who received either rasburicase or allopurinol monotherapy. Goldman/Cairo previously published that rasburicase significantly, more rapidly reduces uric acid exposure (AUC) compared to allopurinol in pts with/at risk of TLS.
Methods
In 2021, 266 oncologists provided anonymized data for 715 liquid tumor pts treated in past year for hyperuricemia (HU) risk and TLS potential. Out of 715, 282 rasburicase and allopurinol pts without spontaneous TLS or TLS before HU treatment (Tx) were matched using 11 pre-HU Tx covariates: acute renal failure, age, anti-cancer Tx, creatinine, gender, LDH, perceived risk, renal disease, tumor type, uric acid, and white blood cells. Matched pts met 1:1, nearest neighbor, caliper matching requirements (width=0.2) of standard deviation of logit of the PSM (d score) on covariates, regardless of whether pts later developed TLS post-HU Tx. Assessments include mean uric acid (UA) levels, anti-cancer Tx, and, as feasible, timing of death relative to HU Tx.
Results
The PSM was almost 0.6 before and near 0 after matching; no covariate had a large imbalance (│d│>0.25) before and after. Of 141 pts in each pt group, TLS-associated mortality was significantly less likely among rasburicase pts (2.1% [n = 3] vs. 7.1% [n = 10], P = 0.047) (71% reduction). Of 63 pt subset who developed TLS after HU Tx, TLS-associated fatalities were even less likely among rasburicase vs. allopurinol pts (8.3% [n = 3] vs. 37% [n = 10], P = 0.005). Comparing 13 who died vs. 269 who lived, no significant difference in mean UA was found (13.5 mg/dL vs. 11.4, respectively). Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) was the predominant Tx among those who did not die (15%, n = 41). Only 1/13 pts died of R-CHOP. Seven pts died within 2 weeks of allopurinol (n = 6) or rasburicase (n = 1) monotherapy (timing not established for other 6).
Conclusions
PSM corrects before and after overall covariate and individual baseline covariate imbalances and rasburicase compared with allopurinol significantly reducing TLS-associated mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
J.R. Gallagher, S. Carroll: Financial Interests, Full or part-time Employment: Clarity Pharma. E.J. Drea, Y.J. Barnes, C. Clark: Financial Interests, Stocks/Shares: Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18